Tags: Search Essay In UrduSteps Of Writing A Business PlanArchitecture Thesis Report On MuseumHomework IsSolve My Math ProblemCollege Essay Examples Ivy LeagueBiographical Essay ExamplesDrugs Sports Research PapersIntroduction On Research Paper
So, at issue here is NOT whether this research is worthwhile, but how journalists handle the “buts” that are inevitable, important, and invaluable.
This is where she encountered one of the investigators.
One thing led to another and, BAM, she qualified and was entered in to the trial.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
What was then heralded as a “watershed moment” and possible “cure” (yes, word was dangled repeatedly) gradually faded to just a moment.
The media frenzy repeated itself again in 2006 — this time when Rosenberg reported using another form of immunotherapy to bring about remission in two people with advanced melanoma.We welcome comments, which users can leave at the end of any of our systematic story reviews or at the end of any of our blog posts.But before leaving a comment, please review these notes about our policy.But I agree any story that focuses on treatment needs to provide more information. 30 years ago I was taught that complete response (no detectable tumor anywhere) frequently translates to survival benefit, while partial response (tumor shrinkage but still detectable) does not.And sadly, breast cancer is among a very few notorious for late recurrences, over 5 years.Heart-warming anecdotes of the fortunate two prevailed over the 15 patients who died. And again, reporters were more smitten than skeptical.Let’s start with the most egregious coverage: this video segment by Dr.They add: In addition, merely generating robust response rates may be no guarantee of an eventual improvement in overall survival …very few surrogate endpoints (such as response rate) have a strong correlation with overall survival in oncology.The prospect of harnessing our own immune system to attack cancer cells is a compelling and worthwhile avenue of research.But as it stands now there’s insufficient evidence to make statements regarding efficacy, safety, costs, or how these treatments stack up against existing therapies.